Concord Biotech Ltd: Stock Analysis & Fundamentals

Updated this week

Concord Biotech Ltd (Pharma - API & CRAMS) — fundamental analysis, earnings data, and key metrics. PE: 33.7. ROE: 21.3%. This stock is not currently in the Nifty 500 momentum outperformers list.

What's Happening

💪Debt reduced 33% YoY — balance sheet strengthening

Key Numbers

Current Price

₹1,015

Dividend Yield

1.05%

Market Cap

10.6K Cr

Valuation

N/A

Other Top Pharma - API & CRAMS Stocks Beating Nifty 500

Gland Pharma Ltd

Average

+15.9%

Acutaas Chemicals Ltd

SMS Pharmaceuticals Ltd

Average • 12w streak

+37.7%

← Back to Pharma - API & CRAMS Dashboard

Frequently Asked Questions: Concord Biotech Ltd

Based on publicly available financial data. This is educational research, not investment advice.

What were Concord Biotech Ltd's latest quarterly results?

Concord Biotech Ltd's latest quarterly results (Dec 2025) show

PAT Growth YoY: -15.8%
Revenue Growth YoY: +13.9%
Operating Margin: 35.0%

What is Concord Biotech Ltd's current PE ratio?

Concord Biotech Ltd's current PE ratio is 33.7x.

Current PE: 33.7x
Market Cap: 10.6K Cr
Dividend Yield: 1.05%

What is Concord Biotech Ltd's price-to-book ratio?

Concord Biotech Ltd's price-to-book ratio is 5.8x.

Price-to-Book (P/B): 5.8x
Book Value per Share: ₹175
Current Price: ₹1015

Is Concord Biotech Ltd a fundamentally strong company?

Concord Biotech Ltd's fundamental strength based on key financial ratios

Return on Capital (ROCE): 28.0%

Is Concord Biotech Ltd debt free?

Concord Biotech Ltd has a debt-to-equity ratio of N/A.

Total Debt: ₹2 Cr

What is Concord Biotech Ltd's return on equity (ROE) and ROCE?

Concord Biotech Ltd's return ratios over recent years

FY2023: ROCE 26.0%
FY2024: ROCE 28.0%
FY2025: ROCE 28.0%

Is Concord Biotech Ltd's cash flow positive?

Concord Biotech Ltd's operating cash flow is positive (FY2025).

Cash from Operations (CFO): ₹245 Cr
Free Cash Flow (FCF): ₹85 Cr
CFO/PAT Ratio: 66% (adequate)

What is Concord Biotech Ltd's dividend yield?

Concord Biotech Ltd's current dividend yield is 1.05%.

Dividend Yield: 1.05%
Current Price: ₹1015

Who holds Concord Biotech Ltd shares — promoters, FII, DII?

Concord Biotech Ltd's shareholding pattern (Dec 2025)

Promoters: 44.1%
FII (Foreign): 7.6%
DII (Domestic): 9.6%
Public: 38.8%

Is promoter holding increasing or decreasing in Concord Biotech Ltd?

Concord Biotech Ltd's promoter holding has remained stable recently.

Current Promoter Holding: 44.1% (Dec 2025)
Previous Quarter: 44.1% (Sep 2025)
Change: 0.00% (stable)

Is Concord Biotech Ltd a new momentum entry or an established outperformer?

Concord Biotech Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.

Is Concord Biotech Ltd worth studying for long term investment?

Based on quantitative research signals, here is why Concord Biotech Ltd may be worth studying

Cash flow is positive — CFO ₹245 Cr

What is the investment thesis for Concord Biotech Ltd?

Concord Biotech Ltd investment thesis summary:

What is the future outlook for Concord Biotech Ltd?

Concord Biotech Ltd's forward outlook based on current data signals

Insufficient data for a forward assessment — monitoring for more signals

The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.